ACR Appropriateness Criteria® Locoregional therapy for resectable oropharyngeal squamous cell carcinomas

Expert Panel on Radiation Oncology – Head and Neck

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: There are no level I studies to guide treatment for resectable oropharyngeal squamous cell carcinoma (SCC). Treatment toxicities influence management recommendations. Ongoing investigations are examining deintensified treatments for human papillomavirus (HPV)-associated oropharyngeal SCC. Methods: The Appropriateness Criteria panel, using modified Delphi methodology, produced a literature summary, an assessment of treatment recommendations, and cases to illustrate their use. Results: A multidisciplinary team produces optimum results. Based on HPV status, smoking history, and staging, patients are divided into groups at low, intermediate, and high-risk of death. In the future, treatment recommendations may be influenced by HPV status, which has changed the epidemiology of oropharyngeal SCC. Conclusion: T1 to T2N0M0 resectable oropharyngeal SCC can be treated with surgery or radiation without chemotherapy. Patients with T1-2N1-2aM0 disease can receive radiation, chemoradiation, or transoral surgery with neck dissection and appropriate adjuvant therapy. Patients with T1-2N2b-3M0 disease should receive chemoradiation or transoral surgery with neck dissection and appropriate adjuvant therapy. Concurrent chemoradiation is preferred for T3 to T4 disease.

Original languageEnglish (US)
Pages (from-to)1299-1309
Number of pages11
JournalHead and Neck
Volume38
Issue number9
DOIs
StatePublished - 2016

Fingerprint

Squamous Cell Carcinoma
Neck Dissection
Therapeutics
Radiation
Epidemiology
Smoking
History
Drug Therapy

Keywords

  • base of tongue cancer
  • human papillomavirus (HPV)
  • oropharyngeal cancer
  • tonsillar cancer
  • transoral robotic surgery (TORS)

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

ACR Appropriateness Criteria® Locoregional therapy for resectable oropharyngeal squamous cell carcinomas. / Expert Panel on Radiation Oncology – Head and Neck.

In: Head and Neck, Vol. 38, No. 9, 2016, p. 1299-1309.

Research output: Contribution to journalArticle

Expert Panel on Radiation Oncology – Head and Neck. / ACR Appropriateness Criteria® Locoregional therapy for resectable oropharyngeal squamous cell carcinomas. In: Head and Neck. 2016 ; Vol. 38, No. 9. pp. 1299-1309.
@article{3d602dd702324dccb3ff07296b4a3da0,
title = "ACR Appropriateness Criteria{\circledR} Locoregional therapy for resectable oropharyngeal squamous cell carcinomas",
abstract = "Background: There are no level I studies to guide treatment for resectable oropharyngeal squamous cell carcinoma (SCC). Treatment toxicities influence management recommendations. Ongoing investigations are examining deintensified treatments for human papillomavirus (HPV)-associated oropharyngeal SCC. Methods: The Appropriateness Criteria panel, using modified Delphi methodology, produced a literature summary, an assessment of treatment recommendations, and cases to illustrate their use. Results: A multidisciplinary team produces optimum results. Based on HPV status, smoking history, and staging, patients are divided into groups at low, intermediate, and high-risk of death. In the future, treatment recommendations may be influenced by HPV status, which has changed the epidemiology of oropharyngeal SCC. Conclusion: T1 to T2N0M0 resectable oropharyngeal SCC can be treated with surgery or radiation without chemotherapy. Patients with T1-2N1-2aM0 disease can receive radiation, chemoradiation, or transoral surgery with neck dissection and appropriate adjuvant therapy. Patients with T1-2N2b-3M0 disease should receive chemoradiation or transoral surgery with neck dissection and appropriate adjuvant therapy. Concurrent chemoradiation is preferred for T3 to T4 disease.",
keywords = "base of tongue cancer, human papillomavirus (HPV), oropharyngeal cancer, tonsillar cancer, transoral robotic surgery (TORS)",
author = "{Expert Panel on Radiation Oncology – Head and Neck} and Beitler, {Jonathan J.} and Harry Quon and Jones, {Christopher U.} and Salama, {Joseph K.} and Busse, {Paul M.} and Cooper, {Jay S.} and Koyfman, {Shlomo A.} and Ridge, {John A.} and Saba, {Nabil F.} and Farzan Siddiqui and Smith, {Richard V.} and Francis Worden and Min Yao and Yom, {Sue S.}",
year = "2016",
doi = "10.1002/hed.24447",
language = "English (US)",
volume = "38",
pages = "1299--1309",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - ACR Appropriateness Criteria® Locoregional therapy for resectable oropharyngeal squamous cell carcinomas

AU - Expert Panel on Radiation Oncology – Head and Neck

AU - Beitler, Jonathan J.

AU - Quon, Harry

AU - Jones, Christopher U.

AU - Salama, Joseph K.

AU - Busse, Paul M.

AU - Cooper, Jay S.

AU - Koyfman, Shlomo A.

AU - Ridge, John A.

AU - Saba, Nabil F.

AU - Siddiqui, Farzan

AU - Smith, Richard V.

AU - Worden, Francis

AU - Yao, Min

AU - Yom, Sue S.

PY - 2016

Y1 - 2016

N2 - Background: There are no level I studies to guide treatment for resectable oropharyngeal squamous cell carcinoma (SCC). Treatment toxicities influence management recommendations. Ongoing investigations are examining deintensified treatments for human papillomavirus (HPV)-associated oropharyngeal SCC. Methods: The Appropriateness Criteria panel, using modified Delphi methodology, produced a literature summary, an assessment of treatment recommendations, and cases to illustrate their use. Results: A multidisciplinary team produces optimum results. Based on HPV status, smoking history, and staging, patients are divided into groups at low, intermediate, and high-risk of death. In the future, treatment recommendations may be influenced by HPV status, which has changed the epidemiology of oropharyngeal SCC. Conclusion: T1 to T2N0M0 resectable oropharyngeal SCC can be treated with surgery or radiation without chemotherapy. Patients with T1-2N1-2aM0 disease can receive radiation, chemoradiation, or transoral surgery with neck dissection and appropriate adjuvant therapy. Patients with T1-2N2b-3M0 disease should receive chemoradiation or transoral surgery with neck dissection and appropriate adjuvant therapy. Concurrent chemoradiation is preferred for T3 to T4 disease.

AB - Background: There are no level I studies to guide treatment for resectable oropharyngeal squamous cell carcinoma (SCC). Treatment toxicities influence management recommendations. Ongoing investigations are examining deintensified treatments for human papillomavirus (HPV)-associated oropharyngeal SCC. Methods: The Appropriateness Criteria panel, using modified Delphi methodology, produced a literature summary, an assessment of treatment recommendations, and cases to illustrate their use. Results: A multidisciplinary team produces optimum results. Based on HPV status, smoking history, and staging, patients are divided into groups at low, intermediate, and high-risk of death. In the future, treatment recommendations may be influenced by HPV status, which has changed the epidemiology of oropharyngeal SCC. Conclusion: T1 to T2N0M0 resectable oropharyngeal SCC can be treated with surgery or radiation without chemotherapy. Patients with T1-2N1-2aM0 disease can receive radiation, chemoradiation, or transoral surgery with neck dissection and appropriate adjuvant therapy. Patients with T1-2N2b-3M0 disease should receive chemoradiation or transoral surgery with neck dissection and appropriate adjuvant therapy. Concurrent chemoradiation is preferred for T3 to T4 disease.

KW - base of tongue cancer

KW - human papillomavirus (HPV)

KW - oropharyngeal cancer

KW - tonsillar cancer

KW - transoral robotic surgery (TORS)

UR - http://www.scopus.com/inward/record.url?scp=84987808218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987808218&partnerID=8YFLogxK

U2 - 10.1002/hed.24447

DO - 10.1002/hed.24447

M3 - Article

C2 - 27330003

AN - SCOPUS:84987808218

VL - 38

SP - 1299

EP - 1309

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 9

ER -